Bank of New York Mellon’s ARS Pharmaceuticals SPRY Stock Holding History

Bank of New York Mellon’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.35M	Buy	168,136 +4,072	+2%	+$35K	﹤0.01%	3187
2026 Q1	$1.32M	Buy	164,064 +1,058	+0.6%	+$10.1K	﹤0.01%	3047
2025 Q4	$1.9M	Buy	163,006 +8,402	+5%	+$81.7K	﹤0.01%	2863
2025 Q3	$1.55M	Buy	154,604 +9,487	+7%	+$136K	﹤0.01%	2951
2025 Q2	$2.53M	Buy	145,117 +12,904	+10%	+$186K	﹤0.01%	2635
2025 Q1	$1.66M	Buy	132,213 +1,975	+2%	+$23.8K	﹤0.01%	2779
2024 Q4	$1.37M	Sell	130,238 -1,373	-1%	-$19.2K	﹤0.01%	2952
2024 Q3	$1.91M	Sell	131,611 -7,674	-6%	-$91.3K	﹤0.01%	2767
2024 Q2	$1.19M	Buy	139,285 +69,394	+99%	+$616K	﹤0.01%	3096
2024 Q1	$714K	Sell	69,891 -14,467	-17%	-$108K	﹤0.01%	3326
2023 Q4	$462K	Buy	84,358 +434	+0.5%	+$1.9K	﹤0.01%	3598
2023 Q3	$317K	Buy	83,924 +7,024	+9%	+$46.1K	﹤0.01%	3778
2023 Q2	$515K	Buy	76,900 +61,715	+406%	+$412K	﹤0.01%	3574
2023 Q1	$98.9K	Hold	15,185	–	–	﹤0.01%	4080
2022 Q4	$130K	Buy	+15,185	New	+$98.5K	﹤0.01%	4079
2022 Q2	–	Sell	-58,644	Closed	-$206K	–	4693
2022 Q1	$206K	Sell	58,644 -1,417	-2%	-$6.17K	﹤0.01%	4222
2021 Q4	$400K	Buy	60,061 +3,393	+6%	+$27.6K	﹤0.01%	3935
2021 Q3	$566K	Buy	56,668 +17,124	+43%	+$422K	﹤0.01%	3741
2021 Q2	$1.22M	Buy	39,544 +4,732	+14%	+$152K	﹤0.01%	3286
2021 Q1	$1.52M	Buy	+34,812	New	+$1.65M	﹤0.01%	3084

Other funds holding SPRY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

Bank of New York Mellon's SPRY Position: Q2 2026 in Review

Bank of New York Mellon increased its ARS Pharmaceuticals (SPRY) stake by 2.5% in Q2 2026, buying an estimated $35K and bringing the position to 168,136 shares worth $1.35M. The position accounts for ﹤0.01% of the portfolio, ranked #3187.

Bank of New York Mellon first reported a position in SPRY in Q1 2021 and has held it in 20 quarters since. The position peaked at $2.53M in Q2 2025. 127 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

Bank of New York Mellon held 168,136 shares of ARS Pharmaceuticals worth $1.35M as of Q2 2026.
Bank of New York Mellon bought 4,072 ARS Pharmaceuticals shares in Q2 2026, an estimated $35K.
ARS Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3187 holding.
Bank of New York Mellon first reported a position in ARS Pharmaceuticals in Q1 2021 and has held it in 20 quarters since.
Bank of New York Mellon's ARS Pharmaceuticals position peaked at $2.53M in Q2 2025.
127 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.